A detailed history of Royal Bank Of Canada transactions in Inhibrx, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 1,324 shares of INBX stock, worth $18,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,324
Previous 15,993 91.72%
Holding current value
$18,761
Previous $607,000 92.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.76 - $39.56 $480,556 - $580,305
-14,669 Reduced 91.72%
1,324 $46,000
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $156,774 - $410,856
10,812 Added 208.69%
15,993 $607,000
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $28,680 - $47,910
1,821 Added 54.2%
5,181 $95,000
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $19,249 - $31,575
1,135 Added 51.01%
3,360 $87,000
Q1 2023

May 15, 2023

SELL
$18.45 - $27.14 $53,486 - $78,678
-2,899 Reduced 56.58%
2,225 $41,000
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $88,469 - $146,118
4,384 Added 592.43%
5,124 $126,000
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $2,211 - $4,723
191 Added 34.79%
740 $13,000
Q2 2022

Aug 15, 2022

SELL
$8.52 - $25.26 $13,214 - $39,178
-1,551 Reduced 73.86%
549 $6,000
Q1 2022

May 16, 2022

SELL
$19.89 - $43.18 $80,614 - $175,008
-4,053 Reduced 65.87%
2,100 $47,000
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $84,155 - $144,778
3,146 Added 104.62%
6,153 $269,000
Q3 2021

Nov 15, 2021

BUY
$25.18 - $37.81 $17,399 - $26,126
691 Added 29.84%
3,007 $100,000
Q2 2021

Aug 16, 2021

BUY
$14.69 - $27.52 $34,022 - $63,736
2,316 New
2,316 $65,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.